![Disc Medicine [Common Shares] Chart](https://www.ariva.de/chart/images/chart.png?z=a172951367~b40~w170x100~Uintraday~YP0~YQ0 "Disc Medicine [Common Shares] Chart")
Jetzt anmelden und diskutieren
Registrieren
Login
Disc Medicine investors who lost money after the FDA issued a Complete Response Letter for bitopertin are encouraged to contact Levi & Korsinsky
NEW YORK, March 18, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP is investigating Disc Medicine, Inc. (NASDAQ: IRON) regarding whether the company adequately communicated risks regarding its bitopertin program before the FDA's issuance of a Complete Response Letter on February 13, 2026, which caused a 21.9% decline in share price. Investors who suffered losses on IRON stock may click here for additional information about this investigation.
The Complete Response Letter for Disc's bitopertin indicated that the FDA required additional data before it could approve the drug for erythropoietic protoporphyria (EPP). The nature of the additional data requirements has not been fully detailed publicly, but the issuance of a CRL typically signals deficiencies in clinical efficacy data, safety concerns, or manufacturing issues that the agency considers unresolved. Each category carries different implications for the timeline and cost of a potential resubmission.
In this instance, the FDA indicated that additional results are necessary to support traditional approval. This means that Disc's timeline for delivering bitopertin will be delayed into 2027 or potentially even further. Clinical trials in ultra-rare diseases like EPP face inherent enrollment challenges due to the small patient population, which can further extend timelines.
Disc's pipeline beyond bitopertin includes earlier-stage programs, but none are near the regulatory stage that would offset the revenue gap created by the CRL. This raises the question of whether additional capital raises will be necessary to fund the bitopertin resubmission while maintaining other development programs. Any dilutive financing could compound losses for existing shareholders who purchased at pre-CRL prices.
Those who purchased IRON shares and want to understand their legal options may contact Levi & Korsinsky by clicking here for a free and confidential discussion.
Levi & Korsinsky, LLP is a national firm with offices in New York, Connecticut, California, and Washington, D.C. that prosecutes securities, derivative, and consumer class actions on behalf of shareholders and consumers; learn more at www.zlk.com.
CONTACT:
Joseph E. Levi, Esq.
Levi & Korsinsky, LLP
33 Whitehall Street, 27th Floor
New York, NY 10004
Tel: (212) 363-7500
Fax: (212) 363-7171
Email: jlevi@levikorsinsky.com
www.zlk.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/iron-drops-up-to-39-after-fda-crl-for-bitopertin----levi--korsinsky-llp-investigates-302716953.html
SOURCE Levi & Korsinsky, LLP
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.
